19 March 2020 in Gastroenterology
3 September 2021 in Cell Death & Disease
The majority of long non-coding RNAs (lncRNAs) have been discovered to be overexpressed in pancreatic cancer (PC) and served as promoters in the tumorigenesis of PC, while the inhibitory functions of lncRNAs in the development of PC have not been fully elucidated yet. LncRNA microarray was adopted to analyze the differential expression of lncRNAs in PC tissues and that in normal peritumoral (NP) tissues. Functional role of lncRNA BM466146.1 on PC was evaluated by gain- and loss-of-function experiments in vivo and in vitro. RNA pull-down, RNA immunoprecipitation, luciferase reporter, and Chromatin-immunoprecipitation assays were performed to assess the mechanism of ZNFTR, respectively. The correlation between the expression of ZNFTR and various clinicopathological characteristics was accessed in PC specimens. This study displayed lncRNA BM466146.1 was downregulated in PC tissues and functioned as a suppressor through regulating the expression of adjacent gene Zinc finger protein 24 (ZNF24), which was assigned as ZNFTR. Mechanistically, ZNFTR interacted with activating transcription factor 3 (ATF3) and sequestered ATF3 away from the ZNF24 promoter, which consequently increased the expression of ZNF24. Further, ZNF24 inhibited the proliferative, metastatic, and pro-angiogenic abilities of PC cells by suppressing transcription of vascular endothelial growth factor A (VEGFA). Therefore, the downregulation of ZNFTR in PC led to the decreased expression of ZNF24, which further resulted in the upregulation of VEGFA to facilitate the development of PC. Meanwhile, ZNFTR was transcriptionally inhibited by the HIF-1α/HDAC1 complex-mediated deacetylation. Clinical results further demonstrated that the low expression of ZNFTR was associated with poor overall survival time. Taken together, our results implicated that ZNFTR was a hypoxia-responsive lncRNA, and functioned as an inhibitor by modulating ATF3/ZNF24/VEGFA pathway in PC.
23 June 2026 in Cancer Research
Fusobacterium nucleatum is a key microbial driver of colorectal cancer progression. In this study, we identified an intercellular signaling axis through which F. nucleatum remodels the immune microenvironment. Analysis of 54 clinical colorectal cancer specimens revealed that high intratumoral F. nucleatum load correlated significantly with PD-L1 upregulation in tumor-associated macrophages, diminished CD8+ T-cell cytotoxicity, and poor patient prognosis. Mechanistically, F. nucleatum infection activated NF-κB signaling in colorectal cancer cells to induce the transcription of the long noncoding RNA mitotically associated long noncoding RNA (MANCR), which was selectively packaged into exosomes via the ESCRT-III/ALIX complex and transferred to macrophages. In recipient macrophages, exosomal MANCR interacted with HNRNP U to increase PD-L1 mRNA stability, leading to sustained PD-L1 surface expression. In humanized mouse models, F. nucleatum exposure inhibited CD8+ T-cell infiltration and suppressed granzyme B activity, thereby compromising antitumor immunity and facilitating tumor proliferation and metastasis. These findings demonstrate that F. nucleatum exploits a tumor-derived exosomal long noncoding RNA network to remotely manipulate macrophage plasticity. Therefore, targeting the F. nucleatum/MANCR/PD-L1 axis may represent a viable strategy to overcome immune resistance in the colorectal cancer microenvironment. Significance: Fusobacterium nucleatum exploits tumor-derived exosomal MANCR to stabilize PD-L1 in macrophages, providing a mechanism of bacterial-driven immune evasion and a potential therapeutic target to restore antitumor immunity in colorectal cancer.